← All trials
NCT03447132
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2018
- Primary completion
- Sep 1, 2023
- Completion date
- Sep 1, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- International Cancer Research Group, United Arab EmiratesLead sponsor
- PfizerCollaborator
- AstraZenecaCollaborator
- Genomic HealthCollaborator
- International Cancer Research Group, United Arab EmiratesStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.